Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Invested Capital (2016 - 2025)

Historic Invested Capital for Perspective Therapeutics (CATX) over the last 15 years, with Q3 2025 value amounting to $242.2 million.

  • Perspective Therapeutics' Invested Capital fell 2625.95% to $242.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $242.2 million, marking a year-over-year decrease of 2625.95%. This contributed to the annual value of $290.7 million for FY2024, which is 28663.46% up from last year.
  • As of Q3 2025, Perspective Therapeutics' Invested Capital stood at $242.2 million, which was down 2625.95% from $265.7 million recorded in Q2 2025.
  • In the past 5 years, Perspective Therapeutics' Invested Capital ranged from a high of $341.0 million in Q2 2024 and a low of $54.6 million during Q4 2022
  • Its 5-year average for Invested Capital is $151.9 million, with a median of $98.8 million in 2023.
  • As far as peak fluctuations go, Perspective Therapeutics' Invested Capital surged by 119065.75% in 2021, and later crashed by 2625.95% in 2025.
  • Perspective Therapeutics' Invested Capital (Quarter) stood at $64.4 million in 2021, then fell by 15.14% to $54.6 million in 2022, then surged by 37.58% to $75.2 million in 2023, then surged by 286.63% to $290.7 million in 2024, then dropped by 16.67% to $242.2 million in 2025.
  • Its Invested Capital was $242.2 million in Q3 2025, compared to $265.7 million in Q2 2025 and $284.6 million in Q1 2025.